Vaccination is a potential prophylactic treatment for atherosclerosis, but vaccine formulation and regime remain to be optimized. Here the authors show, in preclinical mouse models, that vaccination with nanovaccine containing the antigen, p210, and the adjuvant, CpG, conjugated on distinct carriers reaches better efficacy than co-conjugation.
- Lei Zhang
- Abdulrahman AL-Ammari
- Dongping Sun